The FDA on April 8, 2020 approved BRAFTOVI® (Encorafenib), in combination with ERBITUX® (Cetuximab) for the treatment of adult patients with metastatic ColoRectal Cancer (CRC) with a BRAF V600E mutation, detected by an FDA-approved test, after prior therapy. BRAFTOVI® is a product of Array BioPharma Inc.
Bottom Ad
Advertisement
Subscribe
